Mark F. Kubik

Corporate Officer/Principal at GENOR BIOPHARMA HOLDINGS LIMITED

60 year

Health Technology

Consumer Services

Profile

Mark F.
Kubik is currently the Chief Business Officer at Genor Biopharma Holdings Ltd.
He previously worked as the Head of Business Development at Merck & Co., Inc., and as the Chief Business Officer at Actinium Pharmaceuticals, Inc. and OncoImmune, Inc. Kubik received his undergraduate degree from the University of Colorado Boulder and his MBA from The Leeds School of Business.

Mark F. Kubik active positions

Companies	Position	Start
GENOR BIOPHARMA HOLDINGS LIMITED	Corporate Officer/Principal	2021-08-16

All active positions of Mark F. Kubik

Former positions of Mark F. Kubik

Companies	Position	End
OncoImmune, Inc. OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD.	Corporate Officer/Principal	-
MERCK & CO., INC.	Corporate Officer/Principal	-
ACTINIUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

See the detail of Mark F. Kubik's experience

Training of Mark F. Kubik

University of Colorado Boulder	Undergraduate Degree
The Leeds School of Business	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark F. Kubik's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
MERCK & CO., INC.	Health Technology
ACTINIUM PHARMACEUTICALS, INC.	Health Technology
GENOR BIOPHARMA HOLDINGS LIMITED	Health Technology

Private companies	1
OncoImmune, Inc. OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD.	Health Technology